Circadian Rhythms, Sleep, and Disorders of Aging

Trends in Endocrinology and Metabolism

Volumn 27, Issue 4, 2016, Pages 192-203

  Mattis, Joanna ^a   Sehgal, Amita ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aging; Alzheimer's; Circadian rhythms; Huntington's; Neurodegeneration; Parkinson's; Sleep

Indexed keywords

AGING; ALZHEIMER DISEASE; CIRCADIAN RHYTHM; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; GENETIC ANALYSIS; HIGH RISK POPULATION; HUMAN; HUNTINGTON CHOREA; HYGIENE; METABOLISM; MOLECULAR BIOLOGY; NARCOLEPSY; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; SLEEP; SLEEP WAKING CYCLE; SYMPTOM; ANIMAL; PHYSIOLOGY; SLEEP DISORDER;

AGING; ALZHEIMER DISEASE; ANIMALS; CHRONOBIOLOGY DISORDERS; CIRCADIAN RHYTHM; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; SLEEP; SLEEP WAKE DISORDERS;

EID: 84959270340     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.02.003     Document Type: Review

References (143)

1. Miyata S., et al. Poor sleep quality impairs cognitive performance in older adults. J. Sleep Res. 2013, 22:535-541.
2. Goel N., et al. Circadian Rhythms, Sleep Deprivation, and Human Performance 2013, Elsevier. 1st edn.
3. Goel N., et al. Neurocognitive consequences of sleep deprivation. Semin. Neurol. 2009, 29:320-339.
4. Lim J., Dinges D.F. Sleep Deprivation and Vigilant Attention. Ann. N. Y. Acad. Sci. 2008, 1129:305-322.
5. Hardin P.E., Panda S. Circadian timekeeping and output mechanisms in animals. Curr. Opin. Neurobiol. 2013, 23:724-731.
6. Zheng X., Sehgal A. Speed control: cogs and gears that drive the circadian clock. Trends Neurosci. 2012, 35:574-585.
7. Lowrey P.L., Takahashi J.S. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu. Rev. Genomics Hum. Genet. 2004, 5:407-441.
8. Honma S., et al. Suprachiasmatic Nucleus: Cellular Clocks and Networks 2012, Elsevier. 1st edn.
9. Yamazaki S., et al. Resetting central and peripheral circadian oscillators in transgenic rats. Science 2000, 288:682-685.
10. Lehman M.N., et al. Circadian rhythmicity restored by neural transplant. Immunocytochemical characterization of the graft and its integration with the host brain. J. Neurosci. 1987, 7:1626-1638.
11. Ralph M.R., et al. Transplanted suprachiasmatic nucleus determines circadian period. Science 1990, 247:975-978.
12. Kolker D.E., et al. Aging alters circadian and light-induced expression of clock genes in golden hamsters. J. Biol. Rhythms 2003, 18:159-169.
13. Wyse C.A., Coogan A.N. Impact of aging on diurnal expression patterns of CLOCK and BMAL1 in the mouse brain. Brain Res. 2010, 1337:21-31.
14. Chang H.C., Guarente L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 2013, 153:1448-1460.
15. Asai M., et al. Circadian profile of Per gene mRNA expression in the suprachiasmatic nucleus, paraventricular nucleus, and pineal body of aged rats. J. Neurosci. Res. 2001, 66:1133-1139.
16. Davidson A.J., et al. Resetting of central and peripheral circadian oscillators in aged rats. Neurobiol. Aging 2008, 29:471-477.
17. Yamazaki S., et al. Effects of aging on central and peripheral mammalian clocks. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10801-10806.
18. Gibbs J.E., et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc. Natl. Acad. Sci. U.S.A. 2011, 109:582-587.
19. Morioka N., et al. Stimulation of nuclear receptor REV-ERBs regulates tumor necrosis factor-induced expression of proinflammatory molecules in C6 astroglial cells. Biochem. Biophys. Res. Commun. 2016, 469:151-157.
20. Sato S., et al. A circadian clock gene, Rev-erbα, modulates the inflammatory function of macrophages through the negative regulation of Ccl2 expression. J. Immunol. 2014, 192:407-417.
21. Duez H., Staels B. Rev-erbα gives a time cue to metabolism. FEBS Lett. 2008, 582:19-25.
22. Roozendaal B., et al. Changes in vasopressin cells of the rat suprachiasmatic nucleus with aging. Brain Res. 1987, 409:259-264.
23. Nygård M., et al. Age-related changes in electrophysiological properties of the mouse suprachiasmatic nucleus in vitro. Brain Res. Bull. 2005, 65:149-154.
24. Farajnia S., et al. Evidence for neuronal desynchrony in the aged suprachiasmatic nucleus clock. J. Neurosci. 2012, 32:5891-5899.
25. Nakamura T.J., et al. Age-related decline in circadian output. J. Neurosci. 2011, 31:10201-10205.
26. Luo W., et al. Old flies have a robust central oscillator but weaker behavioral rhythms that can be improved by genetic and environmental manipulations. Aging Cell 2012, 11:428-438.
27. Katewa S.D., et al. Peripheral circadian clocks mediate dietary restriction-dependent changes in lifespan and fat metabolism in Drosophila. Cell Metab. 2015, 23:143-154.
28. Sherin J.E., et al. Activation of ventrolateral preoptic neurons during sleep. Science 1996, 271:216-219.
29. Lu J., et al. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J. Neurosci. 2000, 20:3830-3842.
30. De Lecea L., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:322-327.
31. Lee M.G., et al. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. 2005, 25:6716-6720.
32. Adamantidis A.R., et al. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:420-424.
33. Carter M.E., et al. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J. Neurosci. 2009, 29:10939-10949.
34. Peyron C., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998, 18:9996-10015.
35. Carter M.E., et al. Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nat. Neurosci. 2010, 13:1526-1533.
36. Lu J., et al. A putative flip-flop switch for control of REM sleep. Nature 2006, 441:589-594.
37. Weber F., et al. Control of REM sleep by ventral medulla GABAergic neurons. Nature 2015, 526:435-438.
38. Saper C.B., et al. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
39. Abrahamson E.E., et al. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport 2001, 12:435-440.
40. Aston-Jones G., et al. A neural circuit for circadian regulation of arousal. Nat. Neurosci. 2001, 4:732-738.
41. Novak C.M., Nunez A.A. A sparse projection from the suprachiasmatic nucleus to the sleep active ventrolateral preoptic area in the rat. Neuroreport 2000, 11:93-96.
42. Chou T.C., et al. Afferents to the ventrolateral preoptic nucleus. J. Neurosci. 2002, 22:977-990.
43. Thompson R.H., Swanson L.W. Organization of inputs to the dorsomedial nucleus of the hypothalamus: a reexamination with fluorogold and PHAL in the rat. Brain Res. Rev. 1998, 27:89-118.
44. Watts a.G., Swanson L.W. Efferent projections of the suprachiasmatic nucleus: II. Studies using retrograde transport of fluorescent dyes and simultaneous peptide immunohistochemistry in the rat. J. Comp. Neurol. 1987, 258:230-252.
45. Chou T.C., et al. Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms. J. Neurosci. 2003, 23:10691-10702.
46. Redline S., et al. The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture. Arch. Intern. Med. 2004, 164:406-418.
47. Moraes W., et al. Effects of aging on sleep structure throughout adulthood: a population-based study. Sleep Med. 2014, 15:401-409.
48. Huang Y.L., et al. Age-associated difference in circadian sleep-wake and rest-activity rhythms. Physiol. Behav. 2002, 76:597-603.
49. Carskadon M.A., et al. Sleep fragmentation in the elderly: relationship to daytime sleep tendency. Neurobiol. Aging 1982, 3:321-327.
50. Zhdanova I.V., et al. Aging of intrinsic circadian rhythms and sleep in a diurnal nonhuman primate, Macaca mulatta. J. Biol. Rhythms 2011, 26:149-159.
51. Valentinuzzi V.S., et al. Effects of aging on the circadian rhythm of wheel-running activity in C57BL/6 mice. Am. J. Physiol. 1997, 273:R1957-R1964.
52. Van Gool W.A., et al. Age-related changes in circadian sleep-wakefulness rhythms in male rats isolated from time cues. Brain Res. 1987, 413:384-387.
53. Naidoo N., et al. Endoplasmic reticulum stress in wake-active neurons progresses with aging. Aging Cell 2011, 10:640-649.
54. Shiromani P.J., et al. Compensatory sleep response to 12 h wakefulness in young and old rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278:R125-R133.
55. Zhang Y., et al. Effects of aging on light-induced phase-shifting of circadian behavioral rhythms, Fos expression and CREB phosphorylation in the hamster suprachiasmatic nucleus. Neuroscience 1996, 70:951-961.
56. Koh K., et al. A Drosophila model for age-associated changes in sleep:wake cycles. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13843-13847.
57. Sawai N., et al. Developmental and aging change of orexin-A and -B immunoreactive neurons in the male rat hypothalamus. Neurosci. Lett. 2010, 468:51-55.
58. Brownell S.E., Conti B. Age- and gender-specific changes of hypocretin immunopositive neurons in C57Bl/6 mice. Neurosci. Lett. 2010, 472:29-32.
59. Downs J.L., et al. Orexin neuronal changes in the locus coeruleus of the aging rhesus macaque. Neurobiol. Aging 2007, 28:1286-1295.
60. Hunt N.J., et al. Changes in orexin (hypocretin) neuronal expression with normal aging in the human hypothalamus. Neurobiol. Aging 2015, 36:292-300.
61. Terao A., et al. Age-related decline in hypocretin (orexin) receptor 2 messenger RNA levels in the mouse brain. Neurosci. Lett. 2002, 332:190-194.
62. Zhang J-H., et al. Age-related changes in hypocretin (orexin) immunoreactivity in the cat brainstem. Brain Res. 2002, 930:206-211.
63. Bloom G.S. Amyloid-β and Tau. JAMA Neurol. 2014, 71:505.
64. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278.
65. Ju Y-E.S., et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013, 70:587-593.
66. Satlin A., et al. Circadian locomotor-activity and core-body temperature rhythms in Alzheimer's-disease. Neurobiol. Aging 1995, 16:765-771.
67. Van Someren E.J.W., et al. Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol. Psychiatry 1996, 40:259-270.
68. Lee J.H., et al. Daytime sleepiness and functional impairment in Alzheimer disease. Am. J. Geriatr. Psychiatry 2007, 15:620-626.
69. Merlino G., et al. Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: a population-based study. Sleep Med. 2010, 11:372-377.
70. Lee J.H., et al. Twenty-four-hour rhythms of sleep-wake cycle and temperature in Alzheimer's disease. J. Neuropsychiatry 2004, 6:192-198.
71. Hatfield C.F., et al. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia. Brain 2004, 127:1061-1074.
72. Hartmann A., et al. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol. Aging 1997, 18:285-289.
73. Cermakian N., et al. Circadian clock gene expression in brain regions of Alzheimer's disease patients and control subjects. J. Biol. Rhythms 2011, 26:160-170.
74. Stopa E.G., et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J. Neuropathol. Exp. Neurol. 1999, 58:29-39.
75. Zhou J.N., et al. VIP neurons in the human SCN in relation to sex, age, and Alzheimer's-disease. Neurobiol. Aging 1995, 16:571-576.
76. Swaab D.F., et al. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 1985, 342:37-44.
77. Wang J.L., et al. Suprachiasmatic neuron numbers and rest-activity circadian rhythms in older humans. Ann. Neurol. 2015, 78:317-322.
78. Chen K-F., et al. The central molecular clock is robust in the face of behavioural arrhythmia in a Drosophila model of Alzheimer's disease. Dis. Model. Mech. 2014, 7:445-458.
79. Saper C.B., German D.C. Hypothalamic pathology in Alzheimer's disease. Neurosci. Lett. 1987, 74:364-370.
80. Schulz-Schaeffer W.J. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
81. Stern A.L., Naidoo N. Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease. Springerplus 2015, 4:25.
82. Fronczek R., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
83. Thannickal T.C., et al. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
84. Barone P., et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov. Disord. 2009, 24:1641-1649.
85. Chaudhuri K.R., et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov. Disord. 2006, 21:916-923.
86. Diederich N., et al. Progressive sleep "destructuring" in Parkinson's disease. A polysomnographic study in 46 patients. Sleep Med. 2005, 6:313-318.
87. Whitehead D.L., et al. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. Mov. Disord. 2008, 23:1137-1145.
88. Breen D.P., et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 2014, 71:589-595.
89. Bordet R., et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin. Neuropharmacol. 2003, 26:65-72.
90. Videnovic A., et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson's disease. JAMA Neurol. 2014, 71:463-469.
91. Cai Y., et al. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. Eur. J. Neurol. 2010, 17:550-554.
92. Kudo T., et al. Circadian dysfunction in a mouse model of Parkinson's disease. Exp. Neurol. 2011, 232:66-75.
93. Fifel K., Cooper H.M. Loss of dopamine disrupts circadian rhythms in a mouse model of Parkinson's disease. Neurobiol. Dis. 2014, 71:359-369.
94. Iranzo A., et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013, 12:443-453.
95. Schenck C.H., et al. Delayed emergence of a Parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013, 14:744-748.
96. Braak H., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
97. Abbott R.D., et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005, 65:1442-1446.
98. Goodman A.O.G., Barker R.A. How vital is sleep in Huntington's disease?. J. Neurol. 2010, 257:882-897.
99. Aziz N.A., et al. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat. Disord. 2010, 16:345-350.
100. Arnulf I., et al. Rapid eye movement sleep disturbances in Huntington disease. Arch. Neurol. 2008, 65:482-488.
101. Goodman A.O.G., et al. Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. Curr. Neurol. Neurosci. Rep. 2011, 11:211-217.
102. Morton A.J., et al. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 2005, 25:157-163.
103. Pallier P.N., et al. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J. Neurosci. 2007, 27:7869-7878.
104. Fahrenkrug J., et al. Decreased VIP and VPAC2 receptor expression in the biological clock of the R6/2 Huntington's disease mouse. J. Mol. Neurosci. 2007, 31:139-148.
105. Gabery S., et al. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol. 2010, 120:777-788.
106. Aziz A., et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol. 2008, 18:474-483.
107. Levy-lahad A.E., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 2015, 269:973-977.
108. Bélanger V., et al. The circadian regulation of Presenilin-2 gene expression. Chronobiol. Int. 2006, 23:747-766.
109. Zhang S., et al. A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila. Genetics 2010, 184:1165-1179.
110. Means J.C., et al. Drosophila Spaghetti and Doubletime link the circadian clock and light to caspases, apoptosis and tauopathy. PLoS Genet. 2015, 11:e1005171.
111. Krishnan N., et al. The circadian clock gene period extends healthspan in aging Drosophila melanogaster. Aging (Albany NY) 2009, 1:937-948.
112. Krishnan N., et al. Loss of circadian clock accelerates aging in neurodegeneration-prone mutants. Neurobiol. Dis. 2012, 45:1129-1135.
113. Kondratov R.V., et al. Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock. Genes Dev. 2006, 20:1868-1873.
114. Kondratov R.V., et al. Antioxidant N-acetyl-L-cysteine ameliorates symptoms of premature aging associated with the deficiency of the circadian protein BMAL1. Aging (Albany NY) 2009, 1:979-987.
115. Musiek E.S., et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J. Clin. Invest. 2013, 123:5389-5400.
116. Willette A.A., et al. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol. 2015, 53792:1013-1020.
117. Luciano R., et al. Biomarkers of Alzheimer disease, insulin resistance, and obesity in childhood. Pediatrics 2015, 135:1074-1081.
118. Huang Y., Mahley R.W. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol. Dis. 2014, 72:3-12.
119. Szendroedi J., et al. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2011, 8:92-103.
120. Lane-Donovan C., et al. More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron 2014, 83:771-787.
121. Dibner C., Schibler U. Circadian timing of metabolism in animal models and humans. J. Intern. Med. 2015, 277:513-527.
122. Maury E., et al. Circadian disruption in the pathogenesis of metabolic syndrome. Diabetes Metab. 2014, 40:338-346.
123. Weljie A.M., et al. Oxalic acid and diacylglycerol 36:3 are cross-species markers of sleep debt. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:2569-2574.
124. Davies S.K., et al. Effect of sleep deprivation on the human metabolome. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:10761-10766.
125. Taheri S., et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004, 1:e62.
126. Huang Y., et al. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch. Neurol. 2012, 69:51-58.
127. Roh J.H., et al. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci. Transl. Med. 2012, 4:150ra122.
128. Kang J-E., et al. Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
129. Tabuchi M., et al. Sleep Interacts with Aβ to modulate intrinsic neuronal excitability. Curr. Biol. 2015, 25:1-11.
130. Xie L., et al. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377.
131. Rutten S., et al. Bright light therapy in Parkinson's disease: an overview of the background and evidence. Parkinsons Dis. 2012, 2012:1-9.
132. Paus S., et al. Bright light therapy in Parkinson's disease: a pilot study. Mov. Disord. 2007, 22:1495-1498.
133. Wu Y-H., Swaab D.F. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 2007, 8:623-636.
134. Peter-Derex L., et al. Sleep and Alzheimer's disease. Sleep Med. Rev. 2015, 19:29-38.
135. Lim A.S.P., et al. Sleep modifies the relationship of APOE to the risk of Alzheimer disease and neurofibrillary tangle pathology. JAMA Neurol. 2013, 70:1544-1551.
136. Hor H., et al. A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy. Am. J. Hum. Genet. 2011, 89:474-479.
137. Crocker A., et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005, 65:1184-1188.
138. Siegel J.M., et al. Neuronal degeneration in canine narcolepsy. J. Neurosci. 1999, 19:248-257.
139. Gibson E.M., et al. Experimental "jet lag" inhibits adult neurogenesis and produces long-term cognitive deficits in female hamsters. PLoS ONE 2010, 5:e15267.
140. Cho K., et al. Chronic jet lag produces cognitive deficits. J. Neurosci. 2000, 20:RC66.
141. Cho K. Chronic "jet lag" produces temporal lobe atrophy and spatial cognitive deficits. Nat. Neurosci. 2001, 4:567-568.
142. Lim A.S.P., et al. Sleep fragmentation and the risk of incident Alzheimer's disease and cognitive decline in older persons. Sleep 2013, 36:1027-1032.
143. Tranah G.J., et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann. Neurol. 2011, 70:722-732.